参考文献
1.NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines):Vulvar Cancer(Squamous Cell Carcinoma)Version 2.2019 — December 17,2018.
2.American Joint Committee on Cancer (AJCC) Cancer Staging System (8th ed.,2017).
3.Faber MT,Sand FL,Albieri V,et al.Prevalence and type distribution of human papillomavirus in squamous cell carcinoma and intraepithelial neoplasia of the vulva.Int J Cancer 2017, 141:1161-1169.
4.Bogani G,Cromi A,Serati M,et al.Predictors and Patterns of Local,Regional,and Distant Failure in Squamous Cell Carcinoma of the Vulva.Am J Clin Oncol 2017, 40:235-240.
5.Robertson NL,Hricak H,Sonoda Y,et al.The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer.Gynecol Oncol 2016, 140:420-424.
6.Hayes SC,Janda M,Ward LC,et al.Lymphedema following gynecological cancer:Results from a p r o s p e c t i v e,l o n g i t u d i n a l c o h o r t s t u d y o n prevalence,incidence and risk factors.Gynecol Oncol 2017, 146:623-629.
7.Klapdor R,Hillemanns P,Wolber L,et al.Outcome After Sentinel Lymph Node Dissection in Vulvar Cancer:A Subgroup Analysis of the AGO-CaRE-1 Study.Ann Surg Oncol 2017, 24:1314-1321.
8.Rao YJ,Chin RI,Hui C,et al.Improved survival with definitive chemoradiation compared to definitive radiation alone in squamous cell carcinoma of the vulva:A review of the National Cancer Database.Gynecol Oncol 2017, 146:572-579.
9.Woelber L,Eulenburg C,Grimm D,et al.The risk of contralateral nonsentinel metastasis in patients with primary vulvar cancer and unilaterally positive sentinel node.Ann Surg Oncol 2016.
10.Natesan D,Hong JC,Foote J,et al.Primary Versus Preoperative Radiation for Locally Advanced Vulvar Cancer.Int J Gynecol Cancer 2017, 27:794-804.
11.Swanick CW,Eifel PJ,Huo J,et al.Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with nodepositive vulvar cancer.Gynecol Oncol 2017, 146:87-93.(https://www.daowen.com)
12.Salani R,Khanna N,Frimer M,et al.An update on posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies:Society of Gynecologic Oncology (SGO) recommendations.Gynecol Oncol 2017, 146:3-10.
13.Tewari KS,Sill MW,Penson RT,et al.Bevacizumab for advanced cervical cancer:final overall survival and adverse event analysis of a randomised,controlled,openlabel,phase 3 trial (Gynecologic Oncology Group 240).Lancet 2017, 390:1654-1663.
14.Te Grootenhuis NC,van der Zee AG,van Doorn HC,et al.Sentinel nodes in vulvar cancer: Long-term follow-up of the GROningen INternational Study on Sentinel nodes in Vulvar cancer (GROINSS-V) I.Gynecol Oncol 2016, 140:8-14.
15.Frenel JS,Le Tourneau C,O'Neil B,et al.Safety and Efficacy of Pembrolizumab in Advanced,Programmed Death Ligand 1-Positive Cervical Cancer:Results From the Phase Ib KEYNOTE-028 Trial.J Clin Oncol 2017, 35:4035-4041.
16.Le DT,Durham JN,Smith KN,et al.Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.Science 2017, 357:409-413.
17.Swanick CW,Smith GL,Huo J,et al.(P021) Delivery and outcomes of adjuvant radiation therapy in older women with node-positive vulvar cancer.Oncology (Williston Park) 2016, 30.
18.Ignatov T,Eggemann H,Burger E,et al.Adjuvant radiotherapy for vulvar cancer with close or positive surgical margins.J Cancer Res Clin Oncol 2016, 142:489-495.
19.Chung HC,Schellens JH,Delord J-P,et al.Pembrolizumab treatment of advanced cervical cancer:Updated results from the phase 2 KEYNOTE-158 study ［abstract］.J Clin Oncol 2018 36.
20.Arvas M,Kahramanoglu I,Bese T,et al.The Role of Pathological Margin Distance and Prognostic Factors After Primary Surgery in Squamous Cell Carcinoma of the Vulva.Int J Gynecol Cancer 2018, 28:623-631.
21.Li J,Cai Y,Ke G,et al.Validation of the new FIGO staging system (2009) for vulvar cancer in the Chinese population.Gynecol Oncol 2015, 137:274-279.
22.Slomovitz BM,Coleman RL,Oonk MH,et al.Update on sentinel lymph node biopsy for early-stage vulvar cancer.Gynecol Oncol 2015, 138:472-477.